Avoro Capital Advisors LLC Increases Stake in Avidity Biosciences Inc
Avoro Capital Advisors LLC has increased its stake in Avidity Biosciences Inc. by 11.39%, acquiring 870,792 additional shares at $72.13 per share. This move boosts Avoro's total holdings in Avidity Biosciences to 8,515,792 shares, representing 5.54% of its $10.17 billion equity portfolio. Despite Avidity Biosciences being considered significantly overvalued with profitability challenges, Avoro's investment signals confidence in the biotech company's long-term potential and innovative RNA therapeutics pipeline.
Fiera Capital Corp Has $52.39 Million Position in Avidity Biosciences, Inc. $RNA
Fiera Capital Corp significantly increased its stake in Avidity Biosciences, Inc. (NASDAQ:RNA) by 53.8% in Q3, now holding 1,202,384 shares valued at $52.39 million. Several other institutional investors also adjusted their positions in the biotechnology company. Avidity Biosciences is trading at $72.86 with a market cap of $11.27 billion, and analysts have a "Hold" consensus rating on the stock with an average price target of $69.57.
Avidity Biosciences, Inc. $RNA Shares Acquired by Envestnet Asset Management Inc.
Envestnet Asset Management Inc. significantly increased its stake in Avidity Biosciences (NASDAQ:RNA) by 173.2% in the third quarter, while other institutions also boosted their holdings. Despite this institutional interest, analyst sentiment has softened, resulting in a consensus "Hold" rating and a target price of $69.57. Insider selling, including by CEO Sarah Boyce, has been noted as the stock trades near its 52-week high.
Aberdeen Group plc Buys 25,000 Shares of Avidity Biosciences, Inc. $RNA
Aberdeen Group plc increased its stake in Avidity Biosciences, Inc. by 8.9% in the third quarter, purchasing an additional 25,000 shares to bring its total holdings to 304,828 shares valued at $13.28 million. Despite this institutional buying, company insiders, including a director and the CFO, have been net sellers, offloading over 58,000 shares worth approximately $4.23 million in the last quarter. Avidity Biosciences, currently trading near its one-year high, has an average analyst rating of "Hold" with a consensus price target of $69.57.
Avidity Biosciences Reports Del-desiran Clinical Trial Results
Avidity Biosciences reported positive clinical trial results for Del-desiran, demonstrating significant efficacy in reducing DMPK mRNA in patients with myotonic dystrophy type 1 (DM1) and showing functional improvements with a good safety profile. The company is advancing to a global Phase 3 HARBOR study, aiming for Del-desiran to be the first approved drug for DM1. However, recent analyst downgrades occurred due to Novartis's agreement to acquire Avidity Biosciences for $72 per share.
Assetmark Inc. Buys 21,507 Shares of Avidity Biosciences, Inc. $RNA
Assetmark Inc. significantly increased its stake in Avidity Biosciences, purchasing an additional 21,507 shares in the third quarter, bringing its total holdings to 51,186 shares. This institutional buying comes amidst notable insider selling, with the CFO and CEO disposing of shares totaling over $1.3 million. Avidity Biosciences, a clinical-stage biotech developing AOC therapies, currently has a consensus "Hold" rating from analysts with an average price target of $69.57.
Avidity Biosciences (RNA) to Release Earnings on Thursday
Avidity Biosciences (NASDAQ:RNA) is scheduled to release its Q4 2025 earnings before market open on Thursday, February 26th. Analysts anticipate an EPS of ($1.24) and revenue of $1.982 million. The stock recently traded near its 52-week high, and Wall Street maintains a "Hold" consensus rating with a target price of $69.57, despite recent insider share sales.
Avidity’s myotonic dystrophy drug shows promising results in trial By Investing.com
Avidity Biosciences announced promising final results from its Phase 1/2 MARINA trial for delpacibart etedesiran (del-desiran), a drug targeting myotonic dystrophy type 1 (DM1). The drug demonstrated a significant reduction in DMPK mRNA and showed improvements in functional measures with an acceptable safety profile. Currently, del-desiran is undergoing a Phase 3 study, with topline data expected in the second half of 2026.
Avidity’s myotonic dystrophy drug shows promising results in trial
Avidity Biosciences announced promising final results from its Phase 1/2 MARINA trial for delpacibart etedesiran (del-desiran), a drug targeting myotonic dystrophy type 1 (DM1). The study showed a significant reduction in DMPK mRNA and improvements across various functional measures, with an acceptable safety profile. Del-desiran is now in a global Phase 3 HARBOR study, with topline data expected in the second half of 2026.
Avidity Biosciences Acquired by Novartis for $72 per Share
Halper Sadeh LLC is investigating Avidity Biosciences (NASDAQ: RNA) following its acquisition by Novartis for $72 per share in cash, probing potential violations of federal securities laws and fiduciary duties to shareholders. Two analysts, TD Cowen and Chardan, downgraded RNA to Hold and Neutral, respectively, after the merger announcement, adjusting their price targets to reflect the acquisition price. Avidity Biosciences, a biopharmaceutical company focused on RNA therapeutics, aims to expand its pipeline in cardiology and immunology through collaboration with Novartis.
Avidity Biosciences reports data from DMD treatment trials
Avidity Biosciences announced new data from its Phase 1/2 FORTITUDE trial for the Duchenne muscular dystrophy (DMD) treatment, del-ACAMO. The data showed that del-ACAMO led to a mean 48% reduction in dystrophin with expression in 75% of participants, although it did not meet the primary endpoint of increased dystrophin protein expression. The company plans to continue discussions with regulators regarding the path forward for this therapy.
Allianz Asset Management GmbH Invests $632,000 in Avidity Biosciences, Inc. $RNA
Allianz Asset Management GmbH recently acquired a new stake of 14,500 shares, valued at $632,000, in Avidity Biosciences (NASDAQ:RNA) during Q3. This investment comes despite recent insider selling, including CEO Sarah Boyce, totaling over $4.23 million in the past three months. While analysts have a consensus "Hold" rating with an average price target of $69.57, the stock is currently trading near its recent highs.
Avidity Biosciences reports data from DMD treatment trials
Avidity Biosciences has announced new data from its FORTITUDE and EXPLORE clinical trials, which are evaluating the efficacy of del-brax for treating Duchenne Muscular Dystrophy (DMD). The updated information includes 28-week cardiac function data from the FORTITUDE trial and 24-week muscle biopsy data from the EXPLORE trial.
Facioscapulohumeral Muscular Dystrophy Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | Dyne Therapeutics, miRecule, Avidity Biosciences, aTyr Pharma, Fulcrum Therapeutics
The report from DelveInsight offers insights into the Facioscapulohumeral Muscular Dystrophy (FSHD) market, projecting significant growth through 2034, driven by increasing prevalence and pipeline advancements. It highlights key companies like Dyne Therapeutics, miRecule, Avidity Biosciences, aTyr Pharma, and Fulcrum Therapeutics, and discusses upcoming therapies such as delpacibart braxlosiran, EPI-321, and losmapimod. The report also details the current and forecasted epidemiology of FSHD across major markets, emphasizing the unmet need for approved treatments.
Avidity Biosciences, Inc. $RNA Shares Acquired by Candriam S.C.A.
Candriam S.C.A. significantly increased its stake in Avidity Biosciences (NASDAQ:RNA) by 10.2% in Q3, now owning 487,917 shares valued at $21.26 million. Despite this institutional buying, several insiders, including CEO Sarah Boyce, sold substantial amounts of company stock, totaling over $4 million in the last three months. Avidity Biosciences missed its EPS estimate last quarter but saw a significant revenue increase, and the stock currently holds a consensus "Hold" rating from analysts.
Analysts Offer Insights on Healthcare Companies: Pfizer (PFE) and Avidity Biosciences (RNA)
Analysts have issued neutral ratings for Pfizer (PFE) and Avidity Biosciences (RNA), indicating neither a bullish nor bearish outlook. UBS analyst Michael Yee maintained a Hold rating on Pfizer with a $25.00 price target, while Citi's Geoff Meacham kept a Hold rating on Avidity Biosciences with a $72.00 price target. The consensus for Pfizer is a Moderate Buy with a 12.5% upside, and for Avidity Biosciences, it is a Hold with a $75.22 price target.
Avidity Biosciences Announces Expected Record Date for Spin-Off
Avidity Biosciences has announced February 12, 2026, as the expected record date for the spin-off of Atrium Therapeutics. This transaction involves distributing Atrium Therapeutics shares to Avidity shareholders, with each receiving one SpinCo share for every ten Avidity shares. The spin-off aims to separate early-stage cardiology programs and is subject to closing conditions, including a merger with Novartis AG.
Avidity Biosciences Announces Expected Record Date for Spin-Off
Avidity Biosciences has announced February 12, 2026, as the record date for the pro rata distribution of shares of Atrium Therapeutics, Inc. (SpinCo) to Avidity stockholders. This spin-off is part of the proposed acquisition of Avidity by Novartis AG and will see stockholders receive one share of SpinCo for every ten shares of Avidity held. The completion of the merger and spin-off is contingent on closing conditions, including stockholder approval.
Avidity Biosciences receives FTC clearance for Novartis merger
Avidity Biosciences has received clearance from the Federal Trade Commission (FTC) for its merger with Novartis. This regulatory approval is a significant step forward in completing the acquisition, removing a key hurdle for the companies.
Avidity Biosciences Sets February 15, 2026 as Record Date for Planned Spin-Off
Avidity Biosciences has announced February 15, 2026, as the anticipated record date for its planned spin-off. Shareholders of Avidity Biosciences on this date will be eligible to receive shares in the new independent company. This move aims to create two distinct entities, with further details on distribution expected closer to the record date.
Avidity Biosciences Announces Expected Record Date for Spin-Off
Avidity Biosciences has announced February 12, 2026, as the record date for the pro rata distribution of shares of Atrium Therapeutics, Inc. (SpinCo) to Avidity stockholders. This spin-off is part of the previously announced acquisition of Avidity by Novartis AG and the separation of Avidity's early-stage precision cardiology programs into SpinCo. Holders of Avidity common stock on the record date will receive one share of SpinCo common stock for every ten shares of Avidity common stock they own, pending the satisfaction of certain closing conditions, including stockholder approval.
Avidity Biosciences stock hits all-time high at 72.74 USD By Investing.com
Avidity Biosciences stock reached an all-time high of $72.74, reflecting impressive growth with a 120.38% return over the past year and a 102.03% gain in six months. The company maintains financial stability with an $11 billion market capitalization and a current ratio of 11.57, though InvestingPro analysis suggests it might be slightly overvalued. Recent developments include a Managed Access Program for a Duchenne muscular dystrophy therapy and Novartis's agreement to acquire Avidity for approximately $12 billion.
Avidity Biosciences Announces Share Distribution for Spin-Off
Avidity Biosciences has announced a share distribution scheduled for February 12, 2026, where shareholders will receive one share of Atrium Therapeutics for every ten shares of Avidity common stock they own, aiming to boost company value through this spin-off. This distribution is tied to Avidity's acquisition by Novartis, contingent on shareholder approval, and highlights the company's strategic focus on integrating its innovative Antibody Oligonucleotide Conjugates (AOCs™) platform for rare muscle diseases into the larger entity's cardiology and immunology pipelines. Analysts have adjusted their ratings for Avidity Biosciences, citing the merger agreement with Novartis as a key factor in their revised price targets.
Avidity Biosciences (NASDAQ:RNA) Hits New 12-Month High - Here's What Happened
Avidity Biosciences (NASDAQ:RNA) recently hit a new 52-week high of $72.76, closing at $72.6550 with over 1 million shares traded, bringing its market cap to approximately $10.96 billion. Despite this, analyst sentiment remains a "Hold" with an average target of $69.57, and several firms have recently downgraded the stock or cut price targets. Insiders have sold approximately $4.23 million worth of shares in the last three months, and the company missed quarterly EPS estimates while revenue significantly increased year-over-year.
Avidity Biosciences Announces Expected Record Date for Spin-Off
Avidity Biosciences has announced February 12, 2026, as the record date for the pro rata distribution of shares of its spin-off, Atrium Therapeutics, Inc., to existing Avidity stockholders. This spin-off is part of the previously announced acquisition of Avidity by Novartis AG. Both the merger and spin-off are subject to closing conditions, including Avidity stockholder approval, meaning the record date could change.
Avidity Biosciences stock hits all-time high at 72.74 USD
Avidity Biosciences (RNA) stock reached an all-time high of $72.74 USD, driven by significant gains over the past year (120.38%) and last six months (102.03%), demonstrating strong investor confidence. The company, with a market cap of nearly $11 billion and a current ratio of 11.57, is also involved in a Managed Access Program for its Duchenne muscular dystrophy therapy and is set to be acquired by Novartis for approximately $12 billion ($72 per share). Analysts have adjusted ratings and price targets in light of the acquisition.
Atle Fund Management AB Makes New Investment in Avidity Biosciences, Inc. $RNA
Atle Fund Management AB has acquired a new stake of 51,978 shares in Avidity Biosciences (NASDAQ:RNA), valued at approximately $2.27 million. This investment comes as insiders have sold a total of 58,407 shares worth about $4.23 million over the past 90 days, reducing insider ownership to 3.83%. Analysts currently hold a consensus "Hold" rating for the stock, with a price target of $69.57, as RNA trades near its 52-week high.
Mutual of America Capital Management LLC Trims Stake in Avidity Biosciences, Inc. $RNA
Mutual of America Capital Management LLC reduced its stake in Avidity Biosciences (NASDAQ:RNA) by 15.2% in Q3, selling 26,778 shares and now owning 148,849 shares valued at approximately $6.485 million. Insider selling by CEO Sarah Boyce and CFO Michael F. Maclean totaling $1.37 million in late January reflects a broader trend, with insiders selling 58,407 shares in the past 90 days. Despite strong revenue growth (up 420.8% annually), the company missed EPS estimates in its last quarterly report, trades near its 1-year high, and currently holds a consensus "Hold" rating with an average target price of $69.57 among analysts.
EFG Asset Management North America Corp. Reduces Holdings in Avidity Biosciences, Inc. $RNA
EFG Asset Management North America Corp. decreased its stake in Avidity Biosciences, Inc. by 12.0% in Q3, now owning 149,149 shares valued at $6.5 million. The biotechnology company, trading near its 52-week high with a $10.94 billion market cap, reported significant revenue growth but posted negative EPS, and analysts currently rate it as "Hold." Recent insider selling activities, including by CEO Sarah Boyce, also indicate a divestment trend within the company.
Avidity Biosciences CFO MacLean sells $329k in stock By Investing.com
Avidity Biosciences CFO Michael F. MacLean sold 4,542 shares of company stock for approximately $329,067. These sales were "sell-to-cover" transactions to meet tax obligations related to Restricted Stock Units, not discretionary trades. The company is undergoing significant changes, including a planned acquisition by Novartis and the launch of a Managed Access Program for a Duchenne muscular dystrophy therapy.
Avidity Biosciences CSO sells $473k in RNA stock By Investing.com
W. Michael Flanagan, CSO of Avidity Biosciences Inc (NASDAQ:RNA), sold 6,534 shares for $473,388 on January 21, 2026. These sales were non-discretionary, meant to cover tax obligations from vested Restricted Stock Units. The company also announced a Managed Access Program for its Duchenne muscular dystrophy therapy and is set to be acquired by Novartis for about $12 billion.
Avidity Biosciences CSO sells $473k in RNA stock
W. Michael Flanagan, CSO of Avidity Biosciences (NASDAQ: RNA), sold 6,534 shares of stock for approximately $473,388 to cover tax obligations related to Restricted Stock Units. This sale follows news of Novartis's agreement to acquire Avidity Biosciences for $12 billion, leading to analyst downgrades of Avidity's stock. The company is also launching a Managed Access Program for its Duchenne muscular dystrophy therapy.
Avidity Biosciences CFO MacLean sells $329k in stock By Investing.com
Michael F. MacLean, CFO of Avidity Biosciences (NASDAQ:RNA), sold 4,542 shares of common stock for approximately $329,067. These sales were "sell-to-cover" transactions to meet tax obligations related to vested Restricted Stock Units, not discretionary trades. The company is also in the news for a Managed Access Program for a Duchenne muscular dystrophy therapy and a proposed acquisition by Novartis for $12 billion.
Avidity Biosciences (NASDAQ:RNA) Insider Sells $354,642.75 in Stock
Avidity Biosciences insider Steven George Hughes sold 4,895 shares of the company's stock for $354,642.75 on January 21, reducing his ownership by 13.41%. The company, trading near its 52-week high, has a market capitalization of $10.94 billion and reported a negative EPS despite significant revenue growth. Analysts currently rate the stock as "Hold" with an average target price of $69.57.
Avidity Biosciences (NASDAQ:RNA) CFO Sells $329,067.90 in Stock
Avidity Biosciences (NASDAQ:RNA) CFO Michael Maclean sold 4,542 shares of the company's stock for $329,067.90, reducing his ownership by 7.12%. Despite a significant 420.8% year-over-year revenue increase, the company reported an EPS miss and a negative net margin. Analysts currently hold a consensus "Hold" rating for RNA with an average price target of $69.57.
Avidity Biosciences (NASDAQ:RNA) Insider Sells $473,388.30 in Stock
Avidity Biosciences (NASDAQ:RNA) insider W. Michael Flanagan sold 6,534 shares of stock for $473,388.30 on January 21st, reducing his stake by 7.13%. This sale follows another earlier in January and comes as the stock trades near its 52-week high. Analysts currently rate RNA as a "Hold" with a target price of $69.57, despite the company missing EPS estimates but seeing significant revenue growth in Q3.
Avidity Biosciences (NASDAQ:RNA) Director Sells $127,367.10 in Stock
Avidity Biosciences (NASDAQ:RNA) Director Arthur Levin sold 1,758 shares of the company's stock for $127,367.10 on January 21st, reducing his ownership by 9.60%. Following the sale, Levin owns 16,562 shares valued at approximately $1.20 million. The company's stock is trading near its 52-week high, with a market cap of $10.94 billion, and analysts currently have a consensus "Hold" rating with a target price of $69.57.
Avidity Biosciences CMO sells $354k in stock
Steven George Hughes, CMO of Avidity Biosciences (NASDAQ:RNA), sold 4,895 shares of stock worth $354,642 to cover tax withholding obligations from vested RSUs. Following the sale, he directly owns 31,599 shares. This comes amidst recent news of Avidity Biosciences launching a Managed Access Program for delpacibart zotadirsen and Novartis agreeing to acquire the company for $12 billion, leading to analyst downgrades.
Avidity Biosciences CSO sells $473k in RNA stock
W. Michael Flanagan, CSO of Avidity Biosciences (NASDAQ:RNA), sold 6,534 shares for $473,388 to cover tax obligations related to Restricted Stock Units. This transaction is non-discretionary. The company has also launched a Managed Access Program for its Duchenne muscular dystrophy therapy and is set to be acquired by Novartis for $12 billion, leading to analyst downgrades.
Avidity Biosciences stock hits all-time high at $72.70 By Investing.com
Avidity Biosciences stock reached an all-time high of $72.70, marking a 141.25% increase over the past year due to investor confidence in its RNA-based therapies. Recent developments include a Managed Access Program for its Duchenne muscular dystrophy therapy and a significant acquisition by Novartis for approximately $12 billion, leading to analyst downgrades to Neutral/Hold. The company also expects to release Phase 2/3 biomarker data for FSHD in Q2 2026.
Avidity Biosciences stock hits all-time high at $72.70 By Investing.com
Avidity Biosciences Inc. reached an all-time high of $72.70, marking a significant 141.25% increase over the past year due to investor confidence in its RNA-based therapies. Recent news includes a Managed Access Program authorized by the FDA for its Duchenne muscular dystrophy therapy and an agreement for Novartis to acquire Avidity Biosciences for approximately $12 billion, leading to downgrades by Chardan Capital Markets and TD Cowen.
Avidity Biosciences stock hits all-time high at $72.70
Avidity Biosciences Inc. reached an all-time high of $72.70, marking a 141.25% increase over the past year, driven by investor confidence in its RNA-based therapies. The company also announced a Managed Access Program for delpacibart zotadirsen for Duchenne muscular dystrophy patients and will be acquired by Novartis for approximately $12 billion ($72 per share). Following the acquisition news, analysts at Chardan Capital Markets and TD Cowen downgraded the stock and adjusted their price targets.
Avidity reports FTC granted request for early termination of HSR waiting period
Avidity Biosciences announced that the U.S. Federal Trade Commission (FTC) granted its request for early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. This early termination is related to the previously announced private placement in conjunction with its recent stock offering.
Avidity reports FTC granted request for early termination of HSR waiting period
Avidity Biosciences announced that the U.S. Federal Trade Commission (FTC) has granted its request for early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. This early termination is related to the company's previously announced licensing agreement with Bristol Myers Squibb. The agreement focuses on the discovery, development, and commercialization of Avidity's Antibody Oligonucleotide Conjugate (AOC) platform for cardiovascular disease.
Avidity Biosciences, Inc. (RNA) Stock Analysis: Exploring the Biotech Firm’s 434% Revenue Growth and Future Prospects
Avidity Biosciences (RNA) is a biopharmaceutical company specializing in RNA therapeutics with a market cap of $10.93 billion, experiencing 434% revenue growth. Despite a negative EPS and significant free cash flow deficit, common for biotech firms in development, it has a robust clinical pipeline for conditions like myotonic dystrophy and Duchenne muscular dystrophy. Analysts are cautiously optimistic with 2 buy and 12 hold ratings, and the stock shows strong upward technical momentum.
Avidity Biosciences stock hits all-time high at 72.63 USD
Avidity Biosciences Inc (RNA) has reached an all-time high stock price of $72.63, driven by a 160.28% return over the past year and a 128.83% surge in six months, bringing its market capitalization to $10.94 billion. Despite a strong financial position, InvestingPro suggests the stock might be slightly overvalued, although some analysts see a high price target of $96. Recent developments include a Managed Access Program for its investigational therapy for Duchenne muscular dystrophy and an agreement for Novartis to acquire Avidity Biosciences for approximately $12 billion, leading to downgrades from some analysts.
Avidity Biosciences stock hits all-time high at 72.63 USD By Investing.com
Avidity Biosciences (RNA) stock recently hit an all-time high of $72.63, reflecting a 1-year return of 160.28% and a market capitalization of $10.94 billion. This surge in investor confidence is attributed to the company's innovative RNA-based therapeutics. Despite a strong financial position, InvestingPro suggests the stock might be overvalued, although some analysts maintain a higher price target following news of Novartis's agreement to acquire Avidity Biosciences for approximately $12 billion, or $72 per share in cash.
Avidity Biosciences stock hits all-time high at 72.63 USD By Investing.com
Avidity Biosciences stock has reached an all-time high of $72.63, reflecting a 160.28% total return over the past year and a market capitalization of $10.94 billion. This surge in investor confidence is despite some analysts suggesting the stock might be slightly overvalued, with price targets adjusted after Novartis announced plans to acquire Avidity Biosciences for approximately $12 billion.
Avidity Biosciences stock hits all-time high at 72.63 USD
Avidity Biosciences stock reached an all-time high of $72.63, reflecting a 160.28% total return over the past year. This comes amidst a significant acquisition agreement by Novartis for approximately $12 billion, offering $72 per share, which led to downgrades from some analysts. The company also announced a Managed Access Program for its Duchenne muscular dystrophy therapy and is on track to release Phase 2/3 biomarker data for another therapy in 2026.
Insider Selling: Avidity Biosciences (NASDAQ:RNA) Insider Sells 2,374 Shares of Stock
John Moriarty, an insider at Avidity Biosciences (NASDAQ:RNA), recently sold 2,374 shares of the company's stock for over $171,000, reducing his stake by 3.09%. This transaction occurred while shares traded near their one-year high. Avidity Biosciences, an early-stage biotechnology company focused on neuromuscular and cardiac diseases, reported a wider-than-expected quarterly EPS loss but significant revenue growth, and analysts currently have an average "Hold" rating on the stock.
